Resources Repository
-
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Test Performance | Global | Infectious Diseases | Probability/Bayes | Technology Assessment | Health Systems | Policy/Regulation | Government/Law | Health/Medicine | North America -
GuidelinesPublication 2018Latent TB Infection: Updated & Consolidated Guidelines for Programmatic Management
Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation …
Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens with no evidence of clinically manifest active TB. Up to one third of the world’s population is estimated to be infected with Mycobacterium tuberculosis, and on average, 5–10% of those who are infected will develop active TB disease over their lifetime. The management of LTBI involves a comprehensive package of interventions: identifying and testing those individuals…
Evidence Synthesis | Global | Infectious Diseases | Health/Medicine -
GuidelinesPublication 2013Economic Analyses to Support Decisions about HPV Vaccination in Low- and Middle-Income Countries: Consensus Report and Guide
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability …
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability before introducing a program for human papillomavirus (HPV) vaccination. However, many such countries lack the technical capacity and data to conduct their own analyses. This report describes the consensus of an expert group convened by the World Health Organization, prioritizing key issues to be addressed when considering economic analyses to support HPV vaccine introduction in these countries. The expert group…
Health Outcomes | Middle East & North Africa | Infectious Diseases | Costing Methods | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Economics/Finance | Health/Medicine | Science/Technology | Sub-Saharan Africa | Latin America & Caribbean | Asia & Pacific